Wegovy Delays: What the Evidence Says About Gastric Emptying, Periods and More

The gastric emptying delay: what trial data and MHRA guidance confirm

GLP-1 receptor agonists slow gastric emptying through a direct effect on the enteric nervous system and a reduction in gastric contractions. For semaglutide specifically, pharmacokinetic studies show the greatest delay occurs early in the titration schedule, when GLP-1 receptor stimulation is at its most pronounced relative to the gut's adaptation. As the body adjusts over weeks, the magnitude of slowing tends to moderate, though it remains measurable. This is not a side effect to be alarmed by; it is part of the reason people feel full for longer on a smaller meal.

The practical consequence that most patients want to understand is what delayed gastric emptying means for other medicines taken by mouth. Absorption of any oral drug depends partly on how quickly the stomach delivers its contents to the small intestine. Slow that transit and you slow the point at which a tablet dissolves and crosses into the bloodstream. The NHS guidance on weight-management injections addresses this directly, noting that oral medicines taken at the same time as semaglutide may be absorbed more slowly. Our clinical team reviews your full medication list before any prescription is issued, that assessment covers interactions of exactly this kind. You can read more about how the gastric emptying mechanism works on our dedicated gastric emptying page.

For a thorough overview of semaglutide as a medicine, the NHS semaglutide medicines page covers the mechanism, common effects and monitoring points in accessible detail.

Does Wegovy delay or disrupt periods?

Period changes are among the more frequently searched questions about Wegovy, and the honest answer involves separating signal from noise. There is no specific licensed indication relating to menstrual cycles, and the clinical trial programme was not designed to measure cycle regularity as a primary outcome. What researchers and clinicians do observe is that significant weight loss (of the scale Wegovy produces) alters oestrogen metabolism, insulin sensitivity and the hypothalamic signalling that governs the menstrual cycle. Lighter or irregular periods, or a temporary disruption in cycle timing, are not unusual during rapid weight change regardless of the method used to achieve it.

The GLP-1 mechanism adds a secondary layer: reduced caloric intake, nausea-related appetite suppression and the gut-hormone shifts that come with early titration can all influence the hormonal environment. Whether this constitutes a "delay" in the clinical sense varies person to person. For people with polycystic ovary syndrome, weight loss is associated with a return towards more regular cycles, so the picture is not uniformly negative. Our period and Wegovy page goes into the evidence in more depth if that is your primary concern.

One interaction worth knowing: if you take the combined oral contraceptive pill, the absorption timing shift from delayed gastric emptying is relevant. NHS England's guidance on weight-management injections recommends discussing your contraception method with your prescriber before starting, and considering a non-oral method or barrier contraception during titration.

When the delay affects other oral medicines, and what to do about it

The most clinically significant delays from a safety perspective are not period changes but drug-absorption changes. If you take thyroid medication, certain antiepileptics, or any medicine where precise blood levels matter, a shift in absorption timing is worth flagging. The same applies to anyone who takes their oral contraceptive pill at a consistent time: the pill is still likely to be effective, but the timing of peak absorption changes. This is not a reason to avoid Wegovy; it is a reason to have an informed clinical review before starting, and if you are also researching availability, our Wegovy DE page covers how access to the medicine compares across different settings.

A common question is whether these delays ease. The answer is yes, partially. Gastric accommodation improves over the first few months, and by the time most people reach their maintenance dose the acute slowing of the early weeks has moderated. Nausea (which is partly a downstream effect of food sitting in the stomach longer) also tends to settle with each dose step. If you are finding the early weeks difficult, that is a conversation for your prescriber rather than a reason to skip doses; adjusting the titration pace is one of the tools a clinician can use.

You can find a detailed breakdown of how the delayed gastric emptying effect evolves over treatment on our Wegovy delayed gastric emptying page. For broader context on how semaglutide fits into the UK weight-management landscape, our semaglutide overview covers the full picture. If cost is a consideration before you start, our Wegovy price comparison sets out what a legitimate private prescription typically includes. And if you want to explore all available treatment options, our weight-loss treatments overview is a good starting point.

Questions about your specific situation are best answered by a clinician who can see your medical history. If you'd like that conversation, speak to our prescribers, consultations are free, reviewed the same day by a named GPhC-registered prescriber, and there is no obligation to proceed.